STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression

Shinji Kohsaka, Lei Wang, Kazuhiro Yachi, Roshan Mahabir, Takuhito Narita, Tamio Itoh, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, Shinya Tanaka

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive human tumors with a poor prognosis. Current standard treatment includes chemotherapy with the DNA-alkylating agent temozolomide concomitant with surgical resection and/or irradiation. However, a number of cases are resistant to temozolomide-inducedDNA damage due to elevated expression of the DNA repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT). Here, we show that upregulation of both MGMT and STAT3 was accompanied with acquisition of temozolomide resistance in the GBM cell line U87. Inactivation of STAT3 by inhibitor or short hairpin RNA (shRNA) downregulated MGMT expression in GBM cell lines. MGMT upregulation was not observed by the treatment of interleukin (IL)-6 which is a strong activator of STAT3. Contrarily, forced expressedMGMTcould be downregulated by STAT3 inhibitor which was partially rescued by the proteasome inhibitor, MG132, suggesting the STAT3-mediated posttranscriptional regulation of the protein levels of MGMT. Immunohistochemical analysis of 44 malignant glioma specimens showed significant positive correlation between expression levels of MGMT and phosphorylated STAT3 (p-STAT3; P < 0.001, r = 0.58). Importantly, the levels of both MGMT and p-STAT3 were increased in the recurrence compared with the primary lesion in paired identical tumors of 12 cases. Finally, we showed that STAT3 inhibitor or STAT3 knockdown potentiated temozolomide efficacy in temozolomide-resistant GBM cell lines. Therefore, STAT3 inhibitor might be one of the candidate reagents for combination therapy with temozolomide for patients with temozolomide- resistant GBM.

Original languageEnglish
Pages (from-to)1289-1299
Number of pages11
JournalMolecular cancer therapeutics
Volume11
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1
Externally publishedYes

Fingerprint

temozolomide
Methyltransferases
Glioblastoma
Down-Regulation
DNA
Cell Line
O(6)-Methylguanine-DNA Methyltransferase
Up-Regulation
DNA Repair Enzymes
Proteasome Inhibitors
Alkylating Agents
Glioma
Small Interfering RNA
Interleukin-6
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. / Kohsaka, Shinji; Wang, Lei; Yachi, Kazuhiro; Mahabir, Roshan; Narita, Takuhito; Itoh, Tamio; Tanino, Mishie; Kimura, Taichi; Nishihara, Hiroshi; Tanaka, Shinya.

In: Molecular cancer therapeutics, Vol. 11, No. 6, 01.06.2012, p. 1289-1299.

Research output: Contribution to journalArticle

Kohsaka, S, Wang, L, Yachi, K, Mahabir, R, Narita, T, Itoh, T, Tanino, M, Kimura, T, Nishihara, H & Tanaka, S 2012, 'STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression', Molecular cancer therapeutics, vol. 11, no. 6, pp. 1289-1299. https://doi.org/10.1158/1535-7163.MCT-11-0801
Kohsaka, Shinji ; Wang, Lei ; Yachi, Kazuhiro ; Mahabir, Roshan ; Narita, Takuhito ; Itoh, Tamio ; Tanino, Mishie ; Kimura, Taichi ; Nishihara, Hiroshi ; Tanaka, Shinya. / STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. In: Molecular cancer therapeutics. 2012 ; Vol. 11, No. 6. pp. 1289-1299.
@article{b023853f1cd24bd4a30c04fee49ef1bb,
title = "STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression",
abstract = "Glioblastoma multiforme (GBM) is one of the most aggressive human tumors with a poor prognosis. Current standard treatment includes chemotherapy with the DNA-alkylating agent temozolomide concomitant with surgical resection and/or irradiation. However, a number of cases are resistant to temozolomide-inducedDNA damage due to elevated expression of the DNA repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT). Here, we show that upregulation of both MGMT and STAT3 was accompanied with acquisition of temozolomide resistance in the GBM cell line U87. Inactivation of STAT3 by inhibitor or short hairpin RNA (shRNA) downregulated MGMT expression in GBM cell lines. MGMT upregulation was not observed by the treatment of interleukin (IL)-6 which is a strong activator of STAT3. Contrarily, forced expressedMGMTcould be downregulated by STAT3 inhibitor which was partially rescued by the proteasome inhibitor, MG132, suggesting the STAT3-mediated posttranscriptional regulation of the protein levels of MGMT. Immunohistochemical analysis of 44 malignant glioma specimens showed significant positive correlation between expression levels of MGMT and phosphorylated STAT3 (p-STAT3; P < 0.001, r = 0.58). Importantly, the levels of both MGMT and p-STAT3 were increased in the recurrence compared with the primary lesion in paired identical tumors of 12 cases. Finally, we showed that STAT3 inhibitor or STAT3 knockdown potentiated temozolomide efficacy in temozolomide-resistant GBM cell lines. Therefore, STAT3 inhibitor might be one of the candidate reagents for combination therapy with temozolomide for patients with temozolomide- resistant GBM.",
author = "Shinji Kohsaka and Lei Wang and Kazuhiro Yachi and Roshan Mahabir and Takuhito Narita and Tamio Itoh and Mishie Tanino and Taichi Kimura and Hiroshi Nishihara and Shinya Tanaka",
year = "2012",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-11-0801",
language = "English",
volume = "11",
pages = "1289--1299",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression

AU - Kohsaka, Shinji

AU - Wang, Lei

AU - Yachi, Kazuhiro

AU - Mahabir, Roshan

AU - Narita, Takuhito

AU - Itoh, Tamio

AU - Tanino, Mishie

AU - Kimura, Taichi

AU - Nishihara, Hiroshi

AU - Tanaka, Shinya

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Glioblastoma multiforme (GBM) is one of the most aggressive human tumors with a poor prognosis. Current standard treatment includes chemotherapy with the DNA-alkylating agent temozolomide concomitant with surgical resection and/or irradiation. However, a number of cases are resistant to temozolomide-inducedDNA damage due to elevated expression of the DNA repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT). Here, we show that upregulation of both MGMT and STAT3 was accompanied with acquisition of temozolomide resistance in the GBM cell line U87. Inactivation of STAT3 by inhibitor or short hairpin RNA (shRNA) downregulated MGMT expression in GBM cell lines. MGMT upregulation was not observed by the treatment of interleukin (IL)-6 which is a strong activator of STAT3. Contrarily, forced expressedMGMTcould be downregulated by STAT3 inhibitor which was partially rescued by the proteasome inhibitor, MG132, suggesting the STAT3-mediated posttranscriptional regulation of the protein levels of MGMT. Immunohistochemical analysis of 44 malignant glioma specimens showed significant positive correlation between expression levels of MGMT and phosphorylated STAT3 (p-STAT3; P < 0.001, r = 0.58). Importantly, the levels of both MGMT and p-STAT3 were increased in the recurrence compared with the primary lesion in paired identical tumors of 12 cases. Finally, we showed that STAT3 inhibitor or STAT3 knockdown potentiated temozolomide efficacy in temozolomide-resistant GBM cell lines. Therefore, STAT3 inhibitor might be one of the candidate reagents for combination therapy with temozolomide for patients with temozolomide- resistant GBM.

AB - Glioblastoma multiforme (GBM) is one of the most aggressive human tumors with a poor prognosis. Current standard treatment includes chemotherapy with the DNA-alkylating agent temozolomide concomitant with surgical resection and/or irradiation. However, a number of cases are resistant to temozolomide-inducedDNA damage due to elevated expression of the DNA repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT). Here, we show that upregulation of both MGMT and STAT3 was accompanied with acquisition of temozolomide resistance in the GBM cell line U87. Inactivation of STAT3 by inhibitor or short hairpin RNA (shRNA) downregulated MGMT expression in GBM cell lines. MGMT upregulation was not observed by the treatment of interleukin (IL)-6 which is a strong activator of STAT3. Contrarily, forced expressedMGMTcould be downregulated by STAT3 inhibitor which was partially rescued by the proteasome inhibitor, MG132, suggesting the STAT3-mediated posttranscriptional regulation of the protein levels of MGMT. Immunohistochemical analysis of 44 malignant glioma specimens showed significant positive correlation between expression levels of MGMT and phosphorylated STAT3 (p-STAT3; P < 0.001, r = 0.58). Importantly, the levels of both MGMT and p-STAT3 were increased in the recurrence compared with the primary lesion in paired identical tumors of 12 cases. Finally, we showed that STAT3 inhibitor or STAT3 knockdown potentiated temozolomide efficacy in temozolomide-resistant GBM cell lines. Therefore, STAT3 inhibitor might be one of the candidate reagents for combination therapy with temozolomide for patients with temozolomide- resistant GBM.

UR - http://www.scopus.com/inward/record.url?scp=84862577827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862577827&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0801

DO - 10.1158/1535-7163.MCT-11-0801

M3 - Article

VL - 11

SP - 1289

EP - 1299

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -